Influenza can overwhelm the immune system of people with diabetes and lead to fluctuations in blood sugar levels. Now a study has calculated that reducing the likelihood of these complications by vaccinating against flu is associated with a 28% drop in the risk of death.
The seed strain is often to blame for low yields of vaccines to protect against pandemic flu strains H1N1 and H5N1, but Daiichi Sankyo has now encountered difficulties when processing the vaccine, leaving the drugmaker unable to hit the H5N1 vaccine production target it agreed upon with the Japanese government.
Back in November, the GAVI Alliance added inactivated poliovirus vaccines to the list of products it makes available in the world's poorest countries. Now UNICEF is adding its backing, striking a deal with Sanofi to supply the vaccine to GAVI-supported countries for as little as $1 per dose.
A team of U.S. and South African researchers has identified and cloned an antibody that targets one of the few unchanging regions of HIV.
The success of Australia's HPV vaccination catch-up program has given the country a world-leading trove of real-world data on the effectiveness of Merck's Gardasil. By mining this database, researchers have estimated the vaccine halves the risk of young women developing high-grade cervical abnormalities.
While childhood immunization rates show the vast majority of U.S. parents support vaccination, the country is dotted with clusters of people who think the risks outweigh the benefits. Reaching the 10% who decline the measles, mumps and rubella (MMR) vaccine is a challenge for healthcare authorities and research suggests there is no easy solution.
While Finland agreed to pay out in 2011, the U.K. was still knocking back claimants in 2012. Now, though, the U.K. government is reportedly readying to pay 60 people $1.7 million each.
In the decade after Merck began selling its chickenpox vaccine in the U.S. the proportion of infants immunized against the virus rose to almost 90%. Yet immunized kids continued to catch chickenpox and the virus even killed two people who had received the vaccine. This week the Centers for Disease Control and Prevention reported on the success of the strategy it adopted to prevent such cases.
While polio has been eradicated across much of the earth, other viruses from the same family continue to circulate. Many infections are mild or even asymptomatic, but occasionally the viruses can cause the paralysis associated with polio. Over the past 18 months, Stanford University researchers have identified 20 possible cases in California.
At this stage it is unclear if the Taiwanese government would buy the vaccine. Adimmune is continuing development though so it is ready to produce the vaccine if required.
Some studies in low-income countries have shown that widespread immunization can cause unexpected positive consequences. A Danish team has now generated evidence that some of these unintended benefits are seen in wealthy countries, too.
The New York-based drugmaker is keeping the data under wraps until next month but has revealed the headline results. Primary and secondary objectives were all met.
The current flu season should have provided the first opportunity to gauge the impact of quadrivalent vaccines. However, the extra B strain in the quadrivalent vaccines has been rendered irrelevant by the almost total dominance of H1N1.
Strokes are associated with a well-known set of risk factors, yet these triggers only explain 60% of strokes. The causes of the rest--and reasons strokes peak in winter--are unclear, but a growing body of evidence suggests flu vaccines may help to prevent these cases.
The Indian government is negotiating with GlaxoSmithKline and Merck to secure a low-cost supply of human papillomavirus vaccines
The resurgence of H7N9 in recent months has pushed the death toll from the virus up past 70, but so far the bird flu has been mainly limited to bird-to-human transmission on mainland China. However, the seasonal circulation of H7N9 is putting it into contact with other flu viruses, and researchers fear a more contagious, virulent strain could result.
Since eliminating indigenous measles, the U.S. has experienced few cases of the disease. Then in 2011 the country suffered a spate of outbreaks. While most of the disease clusters were small, Centers for Disease Control and Prevention staffers estimate the cost of managing them was up to $5.3 million.
Meningitis A vaccine MenAfriVac has already made its mark on world health, with its nontraditional development model and subsequent success in reducing disease making headlines. Now the World Health Organization is trying to maximize its use by freeing the vaccine from the need to be constantly refrigerated during transport and storage.
While the meningitis B outbreak has died down, the debate it stirred up continues. This week researchers at the Manhattan Institute weighed in with their opinion: If a vaccine is good enough for Europe, it is good enough for the U.S..
Last week research firm GlobalData tipped the hepatitis B vaccine market to top $1 billion by 2022, with sales of Sanofi's Hexyon driving the sector's modest growth. Dynavax hopes to claim a slice of the market too, but its hepatitis B vaccine received another blow this week.